Limitation of multi-drug resistance reversal agents and study advance of new agents

Abstract

The clinical application of multi-drug resistance reversal agents is greatly limited due to its severe side-effects and interference in pharmacokinetics of chemotherapeutic agents. Multi-drug resistance reversal agents haven' t been applicated in clinic successfully. The third generation multi- drug resistance reversal agents, including gefitinib and GF120918, etc, has promising prospect. Key words: Neoplasms ;  Drug tolerance ;  Carrier proteins